404 related articles for article (PubMed ID: 31001918)
21. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
22. MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R.
Wen XP; Ma HL; Zhao LY; Zhang W; Dang CX
Cell Mol Biol (Noisy-le-grand); 2015 May; 61(2):78-85. PubMed ID: 26025408
[TBL] [Abstract][Full Text] [Related]
23. USP52 inhibits cell proliferation by stabilizing PTEN protein in non-small cell lung cancer.
Zhu M; Zhang H; Lu F; Wang Z; Wu Y; Chen H; Fan X; Yin Z; Liang F
Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34533198
[TBL] [Abstract][Full Text] [Related]
24. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
25. Tumour suppressor PTEN enhanced enzyme activity of GPx, SOD and catalase by suppression of PI3K/AKT pathway in non-small cell lung cancer cell lines.
Akca H; Demiray A; Aslan M; Acikbas I; Tokgun O
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):539-44. PubMed ID: 22299584
[TBL] [Abstract][Full Text] [Related]
26. VAOS, a novel vanadyl complexes of alginate saccharides, inducing apoptosis via activation of AKT-dependent ROS production in NSCLC.
Zhou L; Yi Y; Yuan Q; Zhang J; Li Y; Wang P; Xu M; Xie S
Free Radic Biol Med; 2018 Dec; 129():177-185. PubMed ID: 30223019
[TBL] [Abstract][Full Text] [Related]
27. Analysis of miRNA profiles identified miR-196a as a crucial mediator of aberrant PI3K/AKT signaling in lung cancer cells.
Guerriero I; D'Angelo D; Pallante P; Santos M; Scrima M; Malanga D; De Marco C; Ravo M; Weisz A; Laudanna C; Ceccarelli M; Falco G; Rizzuto A; Viglietto G
Oncotarget; 2017 Mar; 8(12):19172-19191. PubMed ID: 27880728
[TBL] [Abstract][Full Text] [Related]
28. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.
Scrima M; De Marco C; Fabiani F; Franco R; Pirozzi G; Rocco G; Ravo M; Weisz A; Zoppoli P; Ceccarelli M; Botti G; Malanga D; Viglietto G
PLoS One; 2012; 7(2):e30427. PubMed ID: 22363436
[TBL] [Abstract][Full Text] [Related]
29. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-561 Affects Proliferation and Cell Cycle Transition Through PTEN/AKT Signaling Pathway by Targeting P-REX2a in NSCLC.
Liao Z; Zheng Q; Wei T; Zhang Y; Ma J; Zhao Z; Sun H; Nan K
Oncol Res; 2020 Mar; 28(2):147-159. PubMed ID: 31711559
[TBL] [Abstract][Full Text] [Related]
31. Long non-coding RNA ASAP1-IT1 promotes cell proliferation, invasion and metastasis through the PTEN/AKT signaling axis in non-small cell lung cancer.
Zhang L; Shi SB; Zhu Y; Qian TT; Wang HL
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(1):142-149. PubMed ID: 29364481
[TBL] [Abstract][Full Text] [Related]
32. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of modulation through PI3K-AKT pathway about Nepeta cataria L.'s extract in non-small cell lung cancer.
Fan J; Bao Y; Meng X; Wang S; Li T; Chang X; Yang G; Bo T
Oncotarget; 2017 May; 8(19):31395-31405. PubMed ID: 28404902
[TBL] [Abstract][Full Text] [Related]
34. B-Myb Mediates Proliferation and Migration of Non-Small-Cell Lung Cancer via Suppressing IGFBP3.
Fan X; Wang Y; Jiang T; Cai W; Jin Y; Niu Y; Zhu H; Bu Y
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772705
[TBL] [Abstract][Full Text] [Related]
35. Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1.
You W; Chen B; Liu X; Xue S; Qin H; Jiang H
Sci Rep; 2017 Apr; 7(1):591. PubMed ID: 28377627
[TBL] [Abstract][Full Text] [Related]
36. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
Shih MC; Chen JY; Wu YC; Jan YH; Yang BM; Lu PJ; Cheng HC; Huang MS; Yang CJ; Hsiao M; Lai JM
Oncogene; 2012 May; 31(19):2389-400. PubMed ID: 21996732
[TBL] [Abstract][Full Text] [Related]
37. miRNA-125b regulates apoptosis of human non-small cell lung cancer via the PI3K/Akt/GSK3β signaling pathway.
Wang Y; Zhao M; Liu J; Sun Z; Ni J; Liu H
Oncol Rep; 2017 Sep; 38(3):1715-1723. PubMed ID: 28713974
[TBL] [Abstract][Full Text] [Related]
38. LSD1 sustains estrogen-driven endometrial carcinoma cell proliferation through the PI3K/AKT pathway via di-demethylating H3K9 of cyclin D1.
Chen C; Wang Y; Wang S; Liu Y; Zhang J; Xu Y; Zhang Z; Bao W; Wu S
Int J Oncol; 2017 Mar; 50(3):942-952. PubMed ID: 28098854
[TBL] [Abstract][Full Text] [Related]
39. PTEN and PI3K/AKT in non-small-cell lung cancer.
Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Faus-Dáder MJ; Calleja-Hernández MÁ
Pharmacogenomics; 2015 Nov; 16(16):1843-62. PubMed ID: 26555006
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological significance of PTEN and PI3K/AKT signal transduction pathway in non-small cell lung cancer.
Yun F; Jia Y; Li X; Yuan L; Sun Q; Yu H; Shi L; Yuan H
Int J Clin Exp Pathol; 2013; 6(10):2112-20. PubMed ID: 24133589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
